Karyopharm Therapeutics Files 8-K on Security Holder Vote

Ticker: KPTI · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1503802

Karyopharm Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyKaryopharm Therapeutics Inc. (KPTI)
Form Type8-K
Filed DateJan 30, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: KPTI

TL;DR

Karyopharm (KPTI) is calling for a shareholder vote on Jan 30th.

AI Summary

Karyopharm Therapeutics Inc. filed an 8-K on January 30, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any financial transactions.

Why It Matters

This filing indicates that Karyopharm Therapeutics Inc. is preparing to hold a vote of its security holders, which could involve significant corporate decisions.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new material financial or operational information.

Key Players & Entities

  • Karyopharm Therapeutics Inc. (company) — Registrant
  • January 30, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-36167 (identifier) — SEC File Number
  • 85 Wells Avenue, 2nd Floor Newton, Massachusetts 02459 (address) — Principal Executive Offices

FAQ

What specific matters will be submitted for a vote by Karyopharm Therapeutics Inc. security holders?

The filing does not specify the exact matters to be submitted for a vote, only that such matters are being presented.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on January 30, 2025.

What is the principal executive office address for Karyopharm Therapeutics Inc.?

The principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.

Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the state of incorporation for Karyopharm Therapeutics Inc.?

Karyopharm Therapeutics Inc. is incorporated in Delaware.

Filing Stats: 895 words · 4 min read · ~3 pages · Grade level 14.7 · Accepted 2025-01-30 16:06:06

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: January 30, 2025 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.